4//SEC Filing
Esposito Pamela 4
Accession 0001193125-25-323090
CIK 0001815442other
Filed
Dec 16, 7:00 PM ET
Accepted
Dec 17, 6:07 PM ET
Size
21.3 KB
Accession
0001193125-25-323090
Insider Transaction Report
Form 4
Esposito Pamela
Director
Transactions
- Exercise/Conversion
Common Stock
2025-12-17$49.10/sh+12,563$616,843→ 12,563 total - Exercise/Conversion
Common Stock
2025-12-17$27.67/sh+12,000$332,040→ 24,563 total - Exercise/Conversion
Common Stock
2025-12-17$31.20/sh+3,000$93,600→ 27,563 total - Sale
Common Stock
2025-12-17$81.56/sh−14,505$1,182,984→ 13,058 total - Sale
Common Stock
2025-12-17$82.34/sh−7,959$655,362→ 5,099 total - Sale
Common Stock
2025-12-17$83.45/sh−4,099$342,064→ 1,000 total - Sale
Common Stock
2025-12-17$84.07/sh−1,000$84,070→ 0 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-12-17−12,563→ 7,500 totalExercise: $49.10Exp: 2031-06-15→ Common Stock (12,563 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2025-12-17−12,000→ 0 totalExercise: $27.67Exp: 2033-06-15→ Common Stock (12,000 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2025-12-17−3,000→ 13,000 totalExercise: $31.20Exp: 2034-06-18→ Common Stock (3,000 underlying)
Footnotes (6)
- [F1]These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 17, 2025 adopted by the reporting person.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.99 to $81.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.99 to $82.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.99 to $83.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.99 to $84.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F6]The shares underlying this stock option are fully vested and exercisable.
Documents
Issuer
Kymera Therapeutics, Inc.
CIK 0001815442
Entity typeother
Related Parties
1- filerCIK 0001744425
Filing Metadata
- Form type
- 4
- Filed
- Dec 16, 7:00 PM ET
- Accepted
- Dec 17, 6:07 PM ET
- Size
- 21.3 KB